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ABSTRACT 
 
Vernal keratoconjunctivitis (VKC) is an allergic condition 
which predominantly affects male children and young adults. VKC 
victims may suffer from symptoms throughout the year, but the 
intensity of signs and symptoms increases during the hot 
seasons. Mast cells appear to play an important role in the 
pathogenesis of VKC. 
Objective: 
This study aims to evaluate from a clinical point of view the 
role of sodium cromoglycate in the treatment of VKC. 
Methods: 
In a single masked interventional study, done in Makkah 
Eye Complex in Khartoum state during the period Jan – June 
2004, 97 patients with vernal keratoconjunctivitis were included in 
this study, 68 patients were the study group using sodium 
cromoglycate eye drops and 29 patients were the control group 
using tears naturale as a placebo. 
A questionnaire designed containing all necessary 
information was completed and full ocular examination for each 
patient was performed. Signs and symptoms were graded and 
recorded in three stages: stage 1(baseline examination), stage 2 
(after 2 weeks) and stage 3 (after 4 weeks). Treatments were 
given to the patients as follows: first two weeks steroids plus 
sodium cromoglycate for the study group and steroid plus placebo 
for the control group. At the end of the first 2 weeks steroid 
stopped and treatment continued with sodium cromoglycate for 
the study group and placebo for the control group for 4 weeks. 
Results: 
Itching and hyperaemia were the main presenting symptom 
and sign of VKC. In the first follow up there was improvement in 
symptoms and signs of both study and control groups and this 
was attributed to the anti-inflammatory effect of steroid. 
In the second follow up there was a significant improvement 
in the symptoms and signs among the study group and this was 
attributed to the mast cell stabilization effect of sodium 
cromoglycate while in the control group the improvement was not 
significant, and some symptoms and signs were getting worse.  
Conclusion: 
Sodium cromoglycate is effective as a prophylactic drug in 
the treatment of VKC.  
  ﺔﻣﻠﺨﺺ ﺍﻻﻃﺮﻭﺣ
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1.1 INTRODUCTION 
Ocular allergy affects 15-20% world-wide population. 
Ninety percent of allergies have ocular symptoms. Ninety 
three percent of patients with hay fever have ocular 
components. Vernal keratoconjunctivitis is a disabling 
disease of children and young adults. It is characterized by 
itching, redness, tearing, foreign body sensation, 
photophobia and thick mucoid discharge.  
Patients of VKC present with conjunctival and corneal 
findings. The conjunctival signs consist of hyperaemia, 
oedema, papillary hypertrophy and giant papillae. The 
limbal signs consist of infiltration with tissue hyperplasia, 
fibrovascular growth, limbal vascularisation and Trantas' 
dots.  
The cornea in VKC may show punctate staining, corneal 
plaque and corneal scars.  
 The reduction in vision is caused either by the sequelae of 
the disease itself (corneal plaque and scars) or as a 
complication of treatment. It is, therefore, conceded that 
continuous research for new drugs that are safe and 
effective and steroid sparing is highly desirable. 
 
Mast cell stabilisers, such as sodium cromoglycate, carry 
very few side effects, but patients need to receive treatment 
for several days before the expected exposure to allergen. 
Maintenance with these topical mast cell stabilizing agents 
during the seasonal period of activity generally keeps the 
symptoms in check. 
Sodium cromoglycate inhibits the degranulation of 
sensitized mast cells that occurs after exposure to specific 
antigen. Through this inhibition sodium cromoglycate 
prevents subsequent release of chemical mediators such 
as histamine that cause hypersensitivity reactions. Sodium 
cromoglycate is used in allergic ocular disorders e.g. 
allergic conjunctivitis, GPC and VKC. It is also used as a 
prophylaxis in asthma, chronic bronchitis, allergic rhinitis 
and food allergy. 
 In Sudan which has a dry dusty hot weather, VKC 
occurrs through out the year. This is what was found by Dr. 
Mohammed Nour Hassan in a study done in 1984. He 
found that the incidence increases during summer from 
April to August and this is related directly to the weather.    
1.2 LITERATURE REVIEW 
1.2.1 GENERAL DESCRIPTION AND FUNCTIONS: 
1.2.1.1Conjunctiva: 
  The conjunctiva is a thin translucent mucous membrane 
which joins the eye ball to the eyelids (1, 2).  It forms a 
smooth, flexible protective sac which covers the pericorneal 
surface of the anterior portion of the eye and lines the 
posterior surface of the eyelids (1, 3).  
Although conjunctiva is continuous, it is conveniently 
described in three regions palpebral, bulber and fornical (1). 
The palpebral conjunctiva extends from the mucocutaneous 
junction at the lid margin to the upper and lower margins of 
the tarsal plates.  
In the fornix, the conjunctiva is loosely attached to the 
orbital septum. The fornical conjunctiva extends temporally 
behind the lateral canthus and nasally to the semilunar fold. 
Ducts of the lacrimal gland open into the temporal portion of 
the upper fornix; those of the accessory glands of Krause 
and Wolfring open into the upper and lower fornices. 
The bulbar conjunctiva is loosely adherent to the sclera and 
extends from the limbus to the fornical area (3).  
 
Histology: Microscopic Structure: 
  As a mucous membrane, conjunctiva has an epithelium 
and sub-mucosal lamina propria (1).  
Epithelium: stratified columnar cells consisting of two to five 
layers. At the limbus there is a change to stratified 
squamous non keratinized epithelium. 
Conjunctival sub-mucosa: consists of fine delicate 
connective tissue which ends at the edges of the cornea (2). 
Blood Supply: 
  The arterial supply of conjunctiva arises from the two 
marginal and peripheral palpebral arches of the eye lid. The 
veins are more numerous than the arteries; they 
accompany the arteries and drain into palpebral veins or 
directly into the superior or inferior ophthalmic veins (2).  
Nerve Supply: 
The sensory innervations of the bulbar conjunctiva are 
from the long ciliary nerves. Innervations of superior 
palpebral conjunctiva and the superior fornix are from the 
frontal and lacrimal nerves. Innervations of inferior 
palpebral conjunctiva and the inferior fornix is from lacrimal 
and infraorbital nerves (2). 
     
 Function: 
The conjunctiva secretes mucus, serves as a repository for 
lacrimal gland and eyelid margin secretions, and aids their 
transportation to the nasolacrimal outflow passages. The intact 
conjunctival epithelial surface and its secretions form a barrier 
to the entrance of exogenous infections and foreign particles. 
Blinking assists in lubricating and moistening the cornea 
through distribution of the tear film, and the smooth palpebral 
surface permits movement of the eyelid over the cornea 
without damage to the corneal surface (3).  
1.2.1.2 Cornea: 
The cornea forms the anterior one sixth of the 
circumference of the outer coat of the eye. The adult cornea 
has an average diameter of approximately 10.6 mm vertically 
and 11.7 mm horizontally (1). The anterior and posterior 
surfaces are parallel to each other in the central 4-mm, 
spherically shaped "optical zone," where the cornea averages 
0.52 mm in thickness. There is a slight flattening of the corneal 
curvature peripherally. In this area, the anterior and posterior 
corneal surfaces are no longer parallel, and the corneal 
thickness increases to an average of 0.65 mm. 
 
The cornea is divisible into five distinct layers:  
Epithelium: 
  Centrally, the epithelium is composed of five to six layers 
of stratified squamous epithelium. Towards the periphery, 
the number of cell layers increases to eight to ten. The 
basal layer of epithelium consists of pale-staining, tall 
polygonal cells containing oval nuclei oriented at a right 
angle to the surface of the cornea. 
Bowman's Layer: 
  Bowman's layer is a uniformly thick acellular structure 
that underlies the basement membrane of the epithelium. 
Bowman's layer is believed to represent a modified layer of 
the anterior stroma and is composed of randomly oriented, 
loosely packed, small collagen fibrils surrounded by 
mucoprotein ground substance. 
Substantia Propria: 
  The substantia propria or stroma, forms approximately 
90% of the thickness of the cornea. It is a vascular and 
consists of collagenous lamellae interspersed with cells 
(keratocytes) and ground substance. The lamellae are 
broad bands of interlacing collagenous fibrils extending  
 
over the entire width of the cornea and arranged almost 
parallel to one another and to its surface. 
Descemet's Membrane: 
Descemet's membrane lies on the posterior aspect of the 
stroma. It is a true basement membrane, being formed by 
corneal endothelial cells. At its periphery, Descemet's 
membrane terminates at the junction between corneal and 
trabecular endothelium. Descemet's membrane is acellular 
and is faintly eosinophilic staining. 
Endothelium: 
The endothelium is a single layer of polygonal cells that 
extends over the inner surface of Descemet's membrane (3).  
Nerve Supply: 
The cornea is richly supplied with unmyelinated nerves 
derived from the ciliary nerves, which are end branches of 
the ophthalmic division of the fifth cranial nerve. The nerves 
are unmyelinated and wrapped by Schwann cells in the 
stroma but not in the corneal epithelium. 
Blood Supply: 
The limbus contains numerous arterial channels, derived 
from the anterior conjunctival and ciliary vessels, as well as 
venous channels from the region of the ciliary body 
(anterior ciliary veins). Their major function is to nourish the 
conjunctiva, episclera, and the sclera in the region of 
Schlemm's canal. The peripheral corneal stroma 
undoubtedly derives a portion of its nourishment from these 
vessels as well. In pathologic states, these vessels serve as 
a source of subepithelial and stromal neovascularization 
(1,3).  
The cornea serves to protect the more delicate structures of 
the anterior segment of the eye from injury. It is also an 
important component of the refractive system of the eye. 
Light incident on the eye is first sharply converged at the 
outer surface of the cornea, where there is an abrupt 
transition in the index of refraction from air (index 1.0) to the 
precorneal tear film (Index 1.37). Minor changes in corneal 
curvature, therefore, can cause relatively large changes in 
refractive power (3). 
1.2.1.3 Tear film: 
  This consists of three layers: 
• Outer lipid layer; secreted by Meibomian glands Its 
function is to retard evaporation of the aqueous layer, 
lower surface tension of the tear film and lubricate the 
eye lids as they pass over the globe.  
• Middle aqueous layer; secreted by lacrimal glands 
and consist of proteins, electrolytes and water. Its 
function is to supply atmospheric oxygen, 
antibacterial function due to the presence of tear 
proteins such as IgA, lysozyme and lactoferrin. To 
abolish any minute irregularities of the anterior 
corneal surface, to wash away debris and noxious 
stimuli and allow the passage of leucocytes after 
injury.  
• Inner mucin layer; secreted by goblet cells, crypts of 
Henle and glands of Manz .Its function is wetting the 
cornea by converting the corneal epithelium from a 
hydrophobic to hydrophilic state (4).  
          
1.2.2 IMMUNOLOGY 
1.2.2.1 Definition: 
Immunity is defined as a host system's response to 
molecules identified as foreign. This concept would then 
encompass immune regulation, with "appropriate" 
responses resulting in beneficial outcomes for the host (i.e., 
control of infection, tumor surveillance) and "inappropriate" 
responses resulting in deleterious outcomes (i.e., 
autoimmune disease, immediate hypersensitivity) (5). 
A specific immune response involves the interaction of 
effector mechanisms such as complement, phagocytes, 
inflammatory cells, and cytokines. However, since these 
responses are not directed against the inciting agent only, 
usually injury to the surrounding host tissue occurs as well. 
Under normal conditions, due to the self-limiting nature of 
immune responses, these injurious reactions are minimal 
and dampened when the foreign antigen is eliminated. In 
addition, due to tolerance to autoantigens, immune 
responses to autologous tissues do not usually occur. In 
some cases, however, when a specific immune response is 
not appropriately controlled, a phenomenon termed 
hypersensitivity ensues (6). 
1.2.2.2 Innate versus acquired immunity:  
The immune response has classically been divided into 
innate and acquired immunity. Innate immunity represents 
the first line of defense for the individual. The chief 
components of innate immunity are the mononuclear 
phagocyte system, including cytokines, complements 
proteins and physiochemical barriers.  
Acquired immunity is defined by the specific recognition 
of foreign molecules by lymphocytes and their products. 
Before exposure to antigens, antigen-specific lymphocytes 
develop, that are capable of recognition and response to 
foreign molecules. This represents the primary response. 
Activation of lymphocytes results in immunologic memory 
with the resultant capacity for dramatic amplification of 
specific and nonspecific effector function on re-exposure to 
the offending molecules, more commonly known as the 
secondary response. The immune system is capable of 
recognizing more than 109 antigenic determinants. This 
remarkably large repertoire results from variability at the 
antigen-binding sites of immunoglobulins and T-cell 
receptors (TCRs) (5).  
 
Acquired immunity can be further subdivided into humoral 
and cell-mediated immunity. Humoral immunity is primarily 
mediated by immunoglobulins, the products of B 
lymphocytes, either in secreted form or as membrane-
bound cell surface receptors. T lymphocytes are primarily 
responsible for cell-mediated immunity. Recognize, 
however, that the interaction between B and T cells is 
crucial in both forms of immunity (5). 
 Antigens: 
 Antigens are molecules capable of specifically binding to 
lymphocyte receptors. More precisely, immunogens are 
those antigens whose binding evokes an immune response. 
Whereas immunoglobulins are capable of binding soluble 
antigens, TCRs bind only processed peptides presented in 
the context of specific cell surface proteins, collectively 
called the major histocompatibility complex (MHC) gene 
products(5). 
1.2.2.3 Physiochemical Barriers:  
In the eye, the conjunctiva and the tear fluid layer provide 
the primary barrier against environmental aeroallergens, 
chemicals, and infectious agents (5). The conjunctiva has a 
rich supply of immunoglobulins. Extracellular IgG, IgA, IgM 
and IgE all of which have been found in the conjunctiva's 
substantia propria, may come from the rich vascular supply, 
the abundant plasma cells, the tear film, the lacrimal gland, 
or more likely, from all four sources(7).  
1.2.2.4 Lymphocytes:  
Lymphocytes are the cells responsible for the specificity 
of immune recognition and for coordination of the immune 
response. They are divided into three classes: T-cells 
lymphocytes, B-cells lymphocytes and natural killer (NK) 
cells. T-cells and B-cells are morphologically 
indistinguishable, small 8 to 10 µm in diameter lymphocytes 
with large nuclei. They are functionally distinct and are 
easily differentiated by the cell surface proteins they 
express: T-cells with CD3, CD4 and CD8 and B-cells with 
CD-19 surface markers.  
B-cells are primarily responsible for humoral immunity 
and are the exclusive producers of immunoglobulins thus 
playing a vital role in the recognition and elimination of 
foreign antigen. Mature B cells can be divided into memory 
cells for the development of a rapid secondary response 
and plasma cells, which are totally committed to produce a 
single protein, an immunoglobulin. Plasma cells are 
terminally differentiated producers of large amounts of 
antibody. B cells also interact closely with helper T cells 
through cell surface proteins such as CD40 and class II 
MHC and their complementary ligands. 
However, an antigen stimulates a polyclonal B-cell 
response, which results in many plasma cells and 
immunoglobulin production of several classes or isotypes (5).  
Mast cells can be divided into two types based on their 
expression of secretory granules: tryptase mast cells (MCT) 
and tryptase-chymase mast cells (MCTC). The predominant 
form of mast cell found in the normal conjunctiva is MCTC; 
however, there is a noticeable increase in the MCT type in 
chronic conjunctival inflammatory conditions. It is estimated 
that more than 50 million mast cells are present in the 
conjunctiva.  
Mast cells and basophils are activated by the cross-
linking of FceRI molecules on their surface after the binding 
of multivalent antigen to sufficient IgE. Activated mast cells 
release their preformed mediators in a regulated fashion and 
then synthesize lipid-derived mediators of inflammation (5).  
 
 
1.2.2.5 Mediators: 
Mediators are biologically active chemical compounds 
contained within inflammatory cells. On release from the 
cell, mediators act in a specific manner and at a specific 
site to induce a component of the inflammatory or 
immunologic process. 
The mast cell surface has as many as 500,000 
immunoglobulin-E (IgE) receptors, 10% of which are 
occupied in vivo. The Fc portion of the IgE molecule, the 
portion attached to the mast cell membrane, changes as a 
result of IgE cross-linking with the offending allergen, 
activating a serine esterase. This leads to an intracellular 
biochemical cascade causing mast cell degranulation and 
the subsequent release of preformed mediators, including 
histamine, eosinophil chemotactic factor of anaphylaxis, 
high-molecular-weight neutrophil chemotactic factor, and 
platelet-activating factor. These mediators attract 
eosinophils and neutrophils, which restore homeostasis to 
the tissue. The signs and symptoms of an acute allergic 
reaction result from this intricate network of mediator 
interaction (5).   
 
The inflammatory process is regulated internally by a 
negative feedback system. The interaction of histamine with 
mast cell surface histamine receptors elevates cyclic 
adenosine monophosphate (cAMP) concentrations, thereby 
"turning off" the mast cell. The second messengers, cAMP 
and cyclic guanosine monophosphate (cGMP), further 
control mediator release from mast cells and basophils. 
Increasing levels of cAMP block mediator release; 
increasing levels of cGMP stimulate mediator release. Beta-
adrenergic receptor activation enhances cAMP levels; 
alpha-adrenergic receptor activation diminishes cAMP 
levels. Prostaglandins act by way of adenyl cyclase to 
increase cAMP levels. Phosphodiesterase degrades cAMP; 
thus, phosphodiesterase inhibitors can increase cAMP 
levels. Cholinergic stimulation results in increasing levels of 
cGMP and mediator release. Thus, allergic symptoms can 
be treated by increasing cAMP levels or decreasing cGMP 
levels. Pharmacologic modulation of these feedback 
mechanisms may provide a novel method for the treatment 
of allergic diseases (5).  
 
 
Preformed Mediators:  
Histamine: 
It is an endogenous substance, widely distributed in 
mammalian tissue. It is stored in the secretory granules of 
tissue mast cells located primarily in connective tissue 
associated with blood vessels. Histamine is also found in 
platelets and in basophils. Re-exposure of sensitized 
individuals to an inciting antigen activates cell-bound IgE 
dimers, inducing mast cell and basophil degranulation and 
resulting in histamine release (5).  
Histamine is the key mediator producing itching, redness 
and chemosis in allergic conjunctivitis (8, 9).  
There are two histamine receptor sites important in allergic 
conjunctivitis: H1 (itch, burn, plus minimal vasodilation) and 
H2 (vasodilation). Histamine levels have been described in 
normal human tears (5 to 10 ng/ml). These levels were 
found to be consistently elevated in the tears of patients 
with active vernal keratoconjunctivitis (VKC; 16 ng/ml) 
(5).This elevation is probably the result of the extensive mast 
cell degranulation demonstrated in patients with VKC by 
light and electron microscopy. In addition, patients with 
VKC have four times as many mast cells in their conjunctiva 
as normal individuals (10), and the location of these mast 
cells is more superficial than in the normal conjunctiva (11), 
such patients are, therefore, at greater risk for antigenic 
attack(5).  
Tryptase:  
Tryptase is a preformed, tetrameric serine endoprotease 
found in mast cells. It is stored in abundant quantities in its 
fully active form. Elevated levels of tryptase have been 
found in tears of patients after eye-rubbing. Tryptase is 
found elevated in patients with VKC even during the 
remission phase (12). 
  Tryptase has the ability to potentiate the effect of 
histamine, activate eosinophils and mast cells, and attract 
eosinophils and neutrophils. Mast cell stabilizers have been 
shown to reduce tryptase levels after allergen challenge (5). 
Chymase: 
Chymase is a serine endoprotease that is stored, 
preformed and fully active, in the TC mast cells. Unlike 
tryptase, chymase is inhibited by plasma proteinase 
inhibitors. The presence of chymase has not yet been 
demonstrated in the eye, although its presence is  
 
suggested by the large number of conjunctival mast cells of the 
MCTC phenotype (5). 
Eosinophil granule major basic protein: 
Eosinophil granule major basic protein (EMBP) accounts 
for more than 50% of the eosinophil granule protein and 
25% of the total cellular protein. 
EMBP is a strongly cationic molecule with a molecular 
weight of 9,300 in humans. VKC is associated with marked 
mast cell degranulation and eosinophil infiltration, providing 
further evidence that eosinophils play a role in tissue 
damage.  
Increased tear levels of both EMBP and Charcot-Leyden 
crystal protein have been detected in patients with VKC. It 
appears that both VKC and contact lens-associated giant 
papillary conjunctivitis are characterized by eosinophil 
degranulation with the release of EMBP and other cytotoxic 
granule proteins that may further stimulate mast cell 
degranulation. The release of EMBP, a powerful epithelial 
toxic compound, may account for keratitis and shield ulcers 
in VKC (5). 
 
 
Oxidative products of Arachidonic acid metabolism:  
Calcium-requiring PLA2 and phospholipase C are rapidly 
activated during an allergic reaction, releasing cholesteryl 
esters. Cell membrane phospholipids are metabolized by 
the cholesteryl ester, leading to the production of 
arachidonic acid. Arachidonic acid is metabolized by two 
major pathways (the cyclooxygenase pathway and the 
lipoxygenase pathway), and the resulting metabolites are 
active inflammatory mediators (5). The addition of aspirin to 
the treatment regimen of patients with intractable VKC has 
produced dramatic improvement in conjunctival and 
episcleral redness, and resolution of keratitis and limbal 
infiltration (8, 13, 14)  indicating that many of the signs and 
symptoms of VKC may be linked to products of the 
cyclooxygenase pathway(8). 
Cyclooxygenase products: 
The cyclooxygenase pathway leads to the production of 
prostaglandins and thromboxanes. The prostaglandins 
PGE1, PGE2, PGF2a, and PGD2 have all been isolated 
from ocular tissue and aqueous humor, but PGD2 is the 
main prostaglandin produced by human mast cells. It 
causes redness, chemosis, mucous discharge, and 
eosinophil chemotaxis in the eye. PGE2 has been shown to 
increase blood flow independently and to synergize with 
histamine, bradykinin, and interleukin (IL)-1 to increase 
vascular permeability. Some evidence suggests that PGF 
may also be involved in allergic disease. Elevated tear 
levels of PGF have been detected in patients with VKC. 
Studies suggest that certain prostaglandins may also have 
anti-inflammatory actions. Thus, prostaglandins may also 
play a role in the negative feedback system that defines the 
allergic response as self-limiting (5). 
Lipoxygenase products: 
Nonsteroidal anti-inflammatory agents such as aspirin 
and indomethacin block the cyclooxygenase pathway, but 
they do not inhibit the production of the lipoxygenase 
products of arachidonic acid. Steroids prevent the release 
of arachidonic acid from membrane phospholipids, perhaps 
by the formation of peptide inhibitors of phospholipase A2, 
thus blocking both the cyclooxygenase and lipoxygenase 
pathways. Therefore, steroids have the ability to block the 
production not only of prostaglandins and thromboxanes, 
but also of leukotrienes(5). 
 
1.2.2.6 Immunoglobulins: 
Immunoglobulins, or antibodies, are the glycoprotein 
products of antigen-stimulated B cells. The only function of 
specialized, terminally differentiated B cells, called plasma 
cells, is the production and secretion of large amounts of 
immunoglobulin, which is found in both membrane-bound 
(serving as B-cell surface receptors) and soluble forms. 
They are widely distributed in plasma and secretory fluids 
such as tears, milk, and mucous.  
Immunoglobulins may be divided into different classes 
based on certain physiochemical characteristics. The 
common physiochemical and antigenic properties of each 
class are based on shared regions of heavy-chain amino 
acid sequences. There are five basic classes, or isotypes: 
IgM, IgD, IgG, IgA, and IgE (5). 
IgM plays a significant role in the primary immune 
response. It is found as a pentamer and accounts for 
approximately 10% of immunoglobulins.  
IgG is the most abundant immunoglobulin in normal human 
serum, accounting for approximately 75% of the total 
immunoglobulin pool.  
 
IgA plays a major role in mucosal immunity. Dimeric IgA 
binds to specific Fc receptors, "secretory components," on 
epithelial cells of organs such as the intestine, as well as on 
the conjunctival surface. The secretory component shuttles 
the dimeric IgA through the cell until it is cleaved at the 
luminal side. Hence, dimeric IgA enters the mucosal lumen 
where it can neutralize pathogens. IgA is the predominant 
immunoglobulin in tear fluid, milk, saliva, and 
tracheobronchial secretions.  
IgE usually is found in small amounts in the serum of 
normal individuals but may be increased greatly in patients 
with atopic disease. It is responsible for immediate 
hypersensitivity reactions and for immunity to parasites. 
CD4+ TH2 cells produce IL-4, which promotes the 
production of IgE. IgE with specific epitopes to allergens 
has been isolated in the tear fluid of patients with atopic 
disorders. 
IgD found on the surface of 50%of B lymphocytes is the 
least common immunoglobulin (5). 
1.2.3 Immunopathology 
The components of the immune system work together to 
ensure the destruction and the elimination of foreign 
organisms or potentially harmful substances globally seen 
by immunocompetent cells as antigens. In certain 
situations, the immune inflammatory response may be 
exaggerated and inappropriate, leading to damage to the 
organism's own tissue in the attempt to eliminate the 
offending agent. These abnormal hypersensitivity reactions 
can be divided into four major groups. The first three are 
primarily mediated by antibodies, whereas the fourth is 
primarily cell dependent (5).  
Type I Hypersensitivity:  
Type I hypersensitivity, also known as mast cell– 
mediated hypersensitivity, is a term that describes a series 
of events that culminate in the activation of a unique set of 
effector cells known as mast cells, resulting in mediator 
release and consequent tissue inflammation(5). The 
initiating event is the interaction between an antigen and its 
specific IgE previously bound to the surface of tissue mast 
cells, resulting in mediator release and consequent tissue 
inflammation(6). This interaction is specific and requires prior 
sensitization. The initial response seems to be the first part 
of a more complex reaction that involves production of 
mediators denovo and their release at a later time to further 
extend the inflammatory reaction by recruiting other effector 
cells, primarily eosinophils. This constitutes the late-phase 
reaction and plays a central role in perpetuating the 
deleterious effects of immediate hypersensitivity. IgE-
mediated mast cell activation is the basic mechanism of 
allergic reactions and atopy. The initial contact with an 
antigen leads to specific immunoglobulin E (IgE) synthesis 
by B cells. Secreted IgE binds to mast cells or basophils 
through high-affinity Fce receptors (FceRI). On subsequent 
exposure to antigen, an immediate hypersensitivity reaction 
is triggered by cross-linking the IgE molecules. 
Environmental factors certainly contribute to the generation 
of clinically significant allergic reactions, but their role has 
yet to be defined. 
 A prerequisite to immediate hypersensitivity is the 
production of specific IgE by B lymphocytes after initial 
exposure to an antigen. These immunoglobulins are 
subsequently bound to Fc receptors on the surface of mast 
cells and basophils. When the organism is re-exposed to 
the same antigen, this interacts with the surface-bound IgE, 
causing cell activation. For antigen antibody interaction to 
activate the cell effectively, cross-linking of at least two 
adjacent IgE molecules must occur. 
Preformed mediators are released from cytoplasmic 
granules by exocytosis. The type and number of mediators 
produced and released by mast cells seem to vary with 
their anatomic location. So-called mucosal mast cells, found 
in the gastrointestinal tract, contain chondroitin sulfate as 
their major granule proteoglycan and little histamine, 
whereas connective tissue mast cells, which are the 
predominant cell type of the periocular tissue, contain 
heparin and release large quantities of histamine. This 
vasoactive amine acts systemically and plays a dominant 
role in determining the clinical manifestations of immediate 
type hypersensitivity. It remains the primary target of most 
therapeutic interventions. Several enzymes present in the 
granules, which also are released in this phase of the 
reaction, may cause local tissue damage, and contribute to 
injury. Activation of mast cells in the ocular mucosa leads to 
chemosis, angioedema, and conjunctivitis (5). 
 
Type II (Cytotoxic) Hypersensitivity: 
In type II hypersensitivity IgG, IgM, and rarely IgA 
mediate antiself reactions that are directed against antigens 
on the surface of one's own cells. The target cells may be 
circulating or components of fixed tissue and antibody-
antigen interaction leads to cell lyses (5). Type II 
hypersensitivity responses are observed in transfusion 
reactions, hemolytic anemia, Good pasture's syndrome, 
pemphigus and myasthenia gravis (6). 
Type III Immune Complex Hypersensitivity: 
Reactions which involve type III hypersensitivity 
responses also are termed immune complex diseases. 
Under normal conditions, when an antibody and an antigen 
combine, an immune complex is formed. These complexes 
usually are cleared from the systemic circulation by 
phagocytes. Ineffectively cleared immune complexes that 
persist in the circulation can lead to systemic disease. This 
type of hypersensitivity is responsible for diseases such as 
systemic lupus erythematosus, polyarteritis nodosa, serum 
sickness and phacoanaphylaxis (6). 
 
 
Type IV Delayed Hypersensitivity:  
Delayed-type hypersensitivity is a cell-mediated immune 
reaction, and unlike the other three types of hypersensitivity 
is not antibody dependent. Recognition of foreign 
substances resides in specific receptor molecules present 
on the membrane of T cells and not in humoral antibodies 
secreted by B cells(5). A common trend in these diseases is 
that the causative agent persists, generating a chronic 
antigenic stimulus. The pathogenesis of sympathetic 
ophthalmia is mediated via a type IV reaction (6).  
 
 
 
 
1.2.4 Vernal Keratoconjunctivitis 
1.2.4.1 Definition:  
Vernal keratoconjunctivitis (VKC) is an allergic 
conjunctival inflammatory disorder with (in most cases) an 
associated secondary keratopathy. VKC is characterized by 
the classic hallmark of giant papillae, usually in the upper 
tarsal conjunctiva but in some instances in the conjunctiva 
at the corneoscleral limbus (16.17). 
It is also defined as a bilateral, recurrent inflammation of the 
conjunctiva (4.18.19). 
1.2.4.2 Epidemiology: 
VKC has a worldwide distribution, with pronounced 
regional variations and prevalence (16). The highest 
incidence of the disease is in the warm temperate (4), Middle 
East-Mediterranean region, and Mexico (6).  It is relatively 
rare in North America and Northern Europe. It may 
represent as much as 3 percent of serious ophthalmic 
disease in some regions whereas in Northern Europe and 
North America the prevalence is approximately 1 in 5000 
cases of eye diseases(16).  
 
 
Age:  
Most series agreed that it affects children and young adults. 
Albert and Jakob found that VKC has been reported to 
affect patients from 1 month of age to more than 70 years 
of age, but at least 50 percent of the patients in most 
reported series are between 5 and 25 years of age (16). The 
peak age of onset is 8 to 12 years, although 10% of VKC 
patients are older than 20 at age of onset (5). Others 
describe it as most common in children between the ages 3 
and 16 (20) or the age range 5-20 years, with peak incidence 
in the age range 11-13 years (6). 
Sex: 
Vernal conjunctivitis most often affects young boys (18, 19, 
21). Boys are affected twice as frequently as girls (6, 22). A 
study by Sayegh F and his collogues found that male 
children were affected about three times more frequently 
than females (23). But the male-to-female ratio evens out 
when the disease affects adults (6, 22).  
While most series describe a male preponderance one 
series points out a female preponderance of patients with 
limbal vernal conjunctivitis when cases are stratified by 
sex(5).  
Seasonal variation:                                                                                          
Vernal is the Latin word for spring. It is a poor name 
because it is more common in climates where there is no 
spring (20). It occurs with the onset of hot weather (18,19), and 
therefore rather a summer than a spring complaint (18). The 
symptoms and signs of VKC may occur on a seasonal 
basis with a peak incidence between April and August but 
many patients have a year-round disease (4,20,23). 
The increase in the pollen count, possibly account for 
exacerbation in the spring (5,6, 21).   
Family history: 
 A family history of atopy is very common (6). There is 
evidence that VKC is an allergic disease, appearing in 
patients who are atopic (i.e., having signs of asthma, 
eczema, or hay fever) (5).  About three quarters of patients 
have associated atopy and two third have a close family 
history of atopy (4). 
The majority of cases of VKC develop a spontaneous 
remission of their disease after puberty (24). They have a 
spontaneous resolution of the disease within 10 years of its 
onset (16). Children usually have self-limited dieses and 
eventually grow out of the disease over a period of 5-10 
years.  Some young adults develop more severe 
manifestation of the disease some times with indefinite 
recurrences (6, 18).   
1.2.4.3 Clinical Feature: 
Symptoms: the main symptoms are intense ocular itching 
associated with lacrimation, photophobia, F.B sensation 
and redness this accompanied by a characteristic white 
ropy secretion caused by increase of viscous mucous in 
tears(4,18,20,24). 
Signs: Three forms of the disease occur; palpebral, limbal 
and mixed.  
The palpebral form is marked by cobblestone papillae on 
the superior tarsal conjunctiva, while the lower lid is 
affected minimally. 
The limbal form is marked by a broad, thickened, 
gelatinous opacification of the superior limbus that can 
over-ride the cornea (6). 
Limbal signs are more common in dark skinned races 
while tarsal and corneal signs predominate in lighter 
skinned races.  
Mixed form in which palpebral and limbal signs coexist (4). 
 
1.2.4.4 Pathology: 
Conjunctiva: 
Tarsal conjunctiva may undergo hyperplasia of its 
epithelium and proliferation of fibrovascular connective 
tissue along with an infiltration of round inflammatory cells 
especially eosinophils and basophils (19). It is easily 
recognized on everting the upper eyelid, palpebral 
conjunctiva is seen to be hypertrophied and mapped out 
into polygonal raised area (18). As the disease progresses 
the papillae become larger and joined together to produce 
giant papillae (20). Papillae that have enlarged often having 
flatten tops. Papillae can be distinguished from follicles by 
their red centers; these centers consist of dilated blood 
vessels at the core of the papillae surrounded by 
inflammatory cells (5). Papillae that form as the result can 
become quite large clinically resembling cobble stone (19). 
A sequel that may occur in VKC is conjunctival scarring that 
has a lacy appearance at the base of the old papillae. 
Although rare, there may be lacy scarring that extends 
superiorly into the fornix. On rare occasions there may be 
conjunctival cysts and enough scarring to cause 
symblepharon formation (5). 
Limbus: 
The epithelium and subepithelial fibrovascular connective 
tissue of the limbal conjunctiva region may undergo 
hyperplasia and round inflammatory cells infiltration with 
production of limbal nodules (19). These changes are 
recognized as thickening and opacification of the limbus (5). 
Limbal nodules appear as gelatinous elevated lesions of the 
superior limbus that can over-ride the cornea (5,6,18). These 
lesions may seem to coalesce and become confluent (5). A 
very characteristic manifestation of limbal vernal 
conjunctivitis is the presence of Horner-Trantas’ dots, which 
are white, chalk-like dots composed of eosinophils and 
epithelial debris (6,18). 
Cornea: 
The cornea can be involved in up to 50% of cases (6). It 
may be severe enough to interrupt a child's education, or if 
uncontrolled it may cause permanent corneal scarring and 
loss of vision (5). Degenerations and death of corneal 
epithelium result in punctate epithelial erosions that are 
especially prone to occur in the upper part of the cornea (19). 
If the inflammation continues, with an outpouring of 
inflammatory mediators into the tear film with associated 
epithelial toxicity and possibly conspiracy from the 
mechanical effects of the large papillae, a frank epithelial 
defect appears next. Such defects have been termed shield 
ulcers because of their position and morphology (16). A 
vernal ulcer of the cornea is a horizontally oval, shallow, 
nonvascularized, indolent ulcer of the superior cornea. The 
edges are composed of shaggy, gray, dead epithelial cells, 
and there is infiltration of the underlying superficial stroma. 
After the ulcer heals, a mild corneal opacity may persist at 
the level of Bowman's layer (6). In general, these ulcers are 
sterile, but there have been rare reports of superimposed 
infectious corneal ulcers occurring in VKC (5).  
Mucus: 
VKC is often accompanied by a thick, tenacious mucous 
discharge that may be so thick that it adheres to the giant 
cobblestones of the upper tarsus. When removed, it may 
form a cast of the cobblestones. Patients report 
symptomatic relief when the stringy, ropy secretions are 
removed from the cul-de-sac (5). 
 
 
 
1.2.4.5 Pathophysiology: 
Type I Hypersensitivity: 
The physiopathology is considered to be of type I 
hypersensitivity reaction (IgE mediated) (25).The mechanism 
of the disease involves fixation of IgE molecules on the 
surface of mast cells and release of mediators, including 
histamine and prostaglandins. Frankland and Easty noted 
that 93% of their 35 patients from the United Kingdom had 
manifestations of atopic disease, including asthma, eczema 
or hay fever, but 7% did not (5). In a survey of IgE levels in 
VKC patients in Israel, tear IgE levels were significantly 
increased in 63.5%, but in 29% of the patients both tear and 
blood IgE levels were normal to low (26). In another study, 
serum IgE levels were elevated in 75% of patients (5). 
Following allergen challenge, tear levels of histamine, kinins 
and thromboxane TxB2 are all elevated (22). In GPC, 30% of 
mast cells appear to be in a degranulated state, while in 
VKC this increases to 80%(10). 
Delayed Hypersensitivity: 
It has been suggested that there is a cell-mediated 
component in vernal conjunctivitis as well, and this has 
been substantiated by studies of the conjunctiva of patients 
with vernal conjunctivitis (27). In chronic allergic disorders 
(AKC, VKC and GPC), CD4+ T-cells numbers are 
increased, with a mixed cellular infiltrate containing many 
mast cells, eosinophils, neutrophils, and macrophages. (26) 
This increased number of T4 helper/inducer cells has been 
confirmed and a further study has shown these cells to be 
the type that can induce the production of IgE antibody (28). 
Abu El-Asrar found numerous stromal lymphocytes. A 
specific type of delayed hypersensitivity known as 
cutaneous basophil hypersensitivity has also been 
implicated and in an animal model the influx of eosinophils 
as well as basophils has added evidence that this type of 
hypersensitivity may be operant (5). 
1.2.4.6 Treatment: 
Nonspecific: 
Cold compresses may alleviate the itching in vernal 
conjunctivitis when it is mild (6, 18). However, when the 
disease is more severe, this treatment is usually not 
effective by itself (5). 
 
 
 
Allergen Avoidance: 
The mainstay of therapy is allergen avoidance (29,) which 
is best evaluated by an allergy specialist (17).Although it is 
usually an unpleasant, expensive, time-consuming, policing 
the patient's environment and scrupulously cleaning it of all 
potential allergen provocateurs is critical to the long-term 
stability of patients with VKC. Involvement by a truly expert 
allergist, who not only can perform the appropriate patch, 
scratch, and prick tests, as well as serum radioallergo - 
sorbent test (RAST), but who also can perform the 
environmental detective work and the motivational and 
educational work necessary for a successful environmental 
control program, is essential. Obviously, the family must be 
convinced of the long-term benefits, not only to the patient 
but also to the family as a whole, before they will seriously 
embark on a complex program that sometimes involves 
removal of expensive carpeting, installation of air 
conditioning, installation of air-filtering systems in the home 
heating system, elimination of beloved pets, and other 
measures. The wisdom, importance, and usefulness of   
this component of the patient's care cannot be over 
emphasized (16). 
Systemic Medication: 
Systemic antihistamines is, superior to topical ocular 
antihistamine therapy in patients with the complicated 
allergic eye diseases, primarily because these diseases last 
so long but also because these allergic individuals 
sometimes become sensitized to the preservatives present 
in the commercially available ocular antihistamines (16). The 
use of terfenadine, 60 mg twice a day, or astemizole, 10 mg 
twice a day, or both, is usually sufficient (16,17). They are 
second generation H1-receptor antagonist. Unlike the first 
generation they do not cross the blood brain barrier to any 
appreciable extend and thus minimally sedating (29).         
 Systemic desensitization immunotherapy may be 
indicated in the patient who has striking sensitivity to a 
limited number of allergens. Performing desensitization 
immunotherapy on a patient with ocular allergy, however, is 
not easy, and some features of this practice are different 
from the typical practice of desensitization immunotherapy 
in the patient with allergies not affecting the eyes (16). 
Topical Medication: 
Topical treatment offers several obvious advantages. 
Eye drops are easily applied and seldom lead to systemic 
side effects. Also, the physical presence of the drops 
themselves will have a washout effect, helping to remove 
the inflammatory mediators and thereby lessening some of 
the symptoms. Topical treatment may also have some 
disadvantages. Vasoconstrictor drops only act for a short 
time and can lead to a rebound vasodilatation (22). Topical 
steroids are effective in reducing the influx of inflammatory 
cells but have little effect on mast cell mediator secretion, 
are slow to act and take several days to achieve their 
maximal effect. They may also have serious side effects, 
such as producing glaucoma, causing cataracts, and 
potentiating infection (24), and so should not be used 
routinely in these conditions.  
Mast cell stabilisers, such as sodium cromoglycate, carry 
very few side effects, but patients need to receive treatment 
for several days before the expected exposure to allergen, 
reducing the tryptase and inflammatory cells after allergen 
challenge (22).Maintenance with these topical mast cell 
stabilizing agent during the seasonal period of activity 
generally keep the symptoms in check (18).  
 
 
Antihistamine-Vasoconstrictors: 
Until recently, topical formulations of antihistamines 
which were developed primarily for systemic administration, 
although having some beneficial effects, were usually not 
potent enough for monotherapy, and had to be 
administered with vasoconstrictors (22).  These preparations 
may have some role in the treatment of mild vernal 
conjunctivitis; however, in the face of onset of any keratitis, 
they do not have the potency necessary to control the 
inflammation (5). 
Levocabastine, developed for topical administration, acts 
within 10 minutes, has a high speed binding affinity for 
histamine H1 receptors, but does not interact with 
cholinergic receptors and has few systemic side effects 
(22).In double-blind comparison of levocabastine eye drops 
with sodium cromoglycate, particularly at high-pollen days, 
levocabastine was superior to cromoglycate in eliminating  
     moderate or severe symptoms (30,31). 
     Mast Cell Stabilizers: 
A series of sequential events occurs in the conjunctival 
mast cells of patients with VKC resulting in the release of 
inflammatory mediators. Several agents, such as disodium 
cromoglycate, have been designed to interfere with the 
release of the mast cell mediators (6, 24), and for the 
treatment of VKC (5). Mast cell stabilizers are one of the 
most commonly used antiallergic agents in ophthalmology   
world wide (29). 
Examination of the first report of cromolyn in VKC is 
important to understand possible differences between 
various studies. In this pioneering study, most patients with 
VKC could be controlled with cromolyn alone. However, 
some required short-term corticosteroids in addition to 
cromolyn, and others required long-term corticosteroids in 
addition to cromolyn. This emphasizes the prophylactic 
nature of the drug and its steroid-sparing qualities (5). 
  Mast cell stabilisers act by preventing calcium influx into 
the mast cells and basophills thus preventing the cascade 
that result in degranulation (29, 32). These are proton H1 
receptor antagonists. Once these mast cells inhibitors are 
bound to a membrane receptor they prevent IgE cross 
linking and thus stabilises the entire excitation process. 
Their mechanism of action also involve increasing 
intracellular cyclic adenosine monophosphate levels 
thereby reducing calcium influx or by inhibiting the enzyme 
nucleosides diphosphate kinase in the cytoplasm. Mast cell 
stabilizers can also act by inhibiting the release of 
neuropeptides from sensory nerve ending (29,33). 
The various agents of this group used in 
ophthalmology are as follows:-  
Cromolyn Sodium (Sodium cromoglycate): 
Indications: in the treatment of allergic ocular disorders 
including vernal Keratoconjunctivitis, giant papillary 
conjunctivitis vernal keratitis and allergic conjunctivitis (29, 34, 
35). 
Sodium cromoglycate inhibits the degranulation of 
sensitized mast cells (20,29)and basophils which occur after 
exposure to specific antigens thus inhibiting the release of 
histamine and SRS-A (slow reacting substance of 
anaphylaxis) from the mast cells(6,29). It has no intrinsic 
vasoconstrictor, antihistamine or anti-inflammatory activity 
(29). Sodium cromoglycate is poorly absorbed and 
approximately 0.03% of it is absorbed following topical 
administration to the eye (29, 32).  Systemically absorbed drug 
is excreted unchanged in the urine. Less than 1%of 
administered dose penetrates into the aqueous humor, and  
clearance from this chamber is almost complete within 24 
hours following discontinuation of treatment (32). 
Onset of therapeutic effect: usually within few days (22, 32). 
One study suggest that it acts within minutes. Sodium 
cromoglycate was statistically better than placebo in 
reducing the symptoms at 2, 10 and 30 minutes after the 
treatment had been administered, showing that topical 
application of 2% sodium cromoglycate can quickly relieve 
ongoing symptoms of allergic inflammation in the eye(36). 
Contraindications: Hypersensitivity to any component of 
its product (29). One patient with an immediate type I 
reaction to DSCG is reported (37). 
 Patients are advised not to wear soft contact lenses during 
treatment (29). Although Iwasaki W conclude that 
commercial DSCG applied topically to contact lenses does 
not result in the accumulation of either the drug or its 
preservatives in lenses and that DSCG can be safely 
applied directly onto a worn contact lens( 38). 
Dosage:  1-2 drops in each eye, 4-6 times a day at regular 
intervals till the desired effect is obtained (29).  In a study to 
compare the efficacy and side effects of sodium 
cromoglycate, eye drops (Opticrom 2%) used (regularly) 
versus (as needed) in the treatment of seasonal allergic 
conjunctivitis. It showed that there is additional therapeutic 
benefit from using sodium cromoglycate eye drops regularly 
throughout the ragweed pollen season (39). 
It is effective alone or in combination with other anti-
allergic drugs (topical or systemic). Symptomatic response 
to the therapy is usually evident within few days but 
treatment should be given up to six weeks or more.  The 
effect of therapy depends upon administration at regular 
intervals and continuity as long as needed to sustain clinical 
improvement. Topical corticosteroids can be used 
concomitantly with cromolyn sodium (29). 
 Adverse reactions:  The most frequent adverse reaction 
reported is ocular stinging or burning sensation upon 
instillation which usually regresses with continued use. 
Other adverse effects reported are conjunctival injection, 
watery itchy and puffy eyes, dryness, irritation and styes (29).         
However, cromolyn is usually not adequate when the eye is 
severely inflamed or when there is a vernal ulcer (5). A good 
strategy by which to control the acute exacerbation of 
symptoms is to start with frequent topical corticosteroids 
combined with topical cromolyn. The corticosteroids are 
then tapered off over a 2-3 week period as the therapeutic 
effects of the cromolyn take hold (6). 
In a double blind study of 22 patients with vernal catarrh, 
sodium cromoglycate eye drops improve the condition of 
the treated eyes. A long term study of up to two years in 61 
patients showed that Keratoconjunctivitis could be 
controlled without topical steroid in 11 patients and with 
only short periods of steroid therapy in 44 patients (33). 
Another study showed that patients using sodium 
cromoglycate were 17 times (95% confidence interval) 
more likely to perceive benefit compared with those using a 
placebo (40). 
In 144 subjects, all had at least a 2-year history of seasonal 
allergic conjunctivitis and were symptomatic at the time of 
inclusion, results for the decrease of main allergic 
conjunctivitis symptoms (itching, tearing and redness) 
showed a marked effect for active treatment on day 3 with a 
sustained improvement on days 7 and 14. A clear response 
to treatment (an improvement of sum scores for day 3 of 
>/=3 points compared to baseline) occurred in 83.0% of 
sodium cromoglycate patients and 56.3% of placebo  
patients (41). The same result was obtained in another study 
(42). 
Topical 4% disodium cromoglycate was found to decrease 
the levels of tryptase in tears of patients with VKC from 
16.77 ng/mL to 7.29 ng/mL(12). 
When comparing 4% disodium cromoglycate and 2% 
disodium cromoglycate; the results indicate that the use of 
4% sodium cromoglycate eye-drops twice daily is as 
effective and well tolerated as 2% sodium cromoglycate 
four times daily in the treatment of birch-pollen 
conjunctivitis( 43). 
 In a retrospective clinical case study; concurrent use of a 
steroid and DSCG provided the most efficacious treatment 
modality for VKC (44). 
Sodium cromoglycate effects on VKC in children: 
A double-masked, coded trial was undertaken to 
evaluate the effect of the topical administration of 2% 
cromolyn sodium eye drops on vernal keratoconjunctivitis in 
14 children. One eye of each patient was treated for one 
year with cromolyn, the other eye with placebo. Cromolyn 
reduced the characteristic vernal keratitis, vernal corneal 
ulcers and plaques, and limbal oedema and infiltrates but 
did not affect the number or size of the giant papillae. The 
drug's long-term topical use did not have any adverse side 
effects (45). 
In black children in Southern Africa a combination of 
steroids and SCG proved particularly effective in treating 
severe cases, indicating a possible synergistic effect of the 
2 drugs (46). 
Nedocromil: 
It is a disodium salt of pyranoquinoline dicarboxylic acid.  
Nedocromil prevents chemotactic and inflammatory 
mediator release from the effector cells such as 
granulocytes, monocytes, macrophages and mast cells (29). 
In comparison to DSCG, nedocromil is more effective in 
controlling symptoms of VKC (47), but when compared with 
fluorometholone, fluorometholone was significantly more 
effective than Nedocromil (24).  
It is tried in concentration of 1 percent to be given 1-2 drops 
4 times a day. No serious side effects have been reported 
with the use of this drug.  
Lodoxamide:                                                                        
It is a most potent topical mast cell inhibitor. It effectively  
prevents histamine release from mast cells during 
immediate hypersensitivity reactions. 
Lodoxamide significantly reduces recruitment of neutrophils 
and eosinophils and prevents mast cell degranulation. 
Inhibition of leukocyte, monocyte and eosinophils activation 
by mast cell stabilizers is important in modifying the allergic 
inflammatory response. It stabilises the mast cell response 
in vernal conjunctivitis and has dual mechanism of action. 
Indications: it is highly effective in treatment of vernal 
Keratoconjunctivitis (VKC), giant papillary conjunctivitis 
(GPC) and atopic Keratoconjunctivitis (AKC). Lodoxamide 
is more efficacious than DSCG with earlier improvement of 
signs and symptoms (48).It is most effective in VKC and for 
sustained relief of signs and symptoms and treatment of 
corneal complications.  
Dosage: it is available as 0.1 percent ophthalmic 
suspension (Lodoxamide   tromethamine). The usual 
dosage is to instill 1-2 drops in the affected eyes 4 times a 
day throughout the year. It should be instilled at regular 
intervals for better response. 
Adverse reactions:  adverse effects have been reported 
with topical lodoxamide use; transient burning and stinging 
sensation, ocular itching, dry eye, blurred vision, tearing, 
discharge, hyperemia, crystalline deposits, foreign body 
sensation, rarely chemosis, corneal abrasion, keratitis, 
blepharitis, allergy, etc, which regresses with regular and 
continuous use of  lodoxamide (29). 
Other new mast cell inhibitors: 
Ketotifen fumarate: 
Ketotifen is a relatively selective non competitive 
histamine antagonist (H1 receptor and mast cell stabilizer). 
Ketotifen inhibits the release of mediators from cells 
involved in hypersensitivity reactions. Decrease chemotaxis 
and eosinophils activation have also been shown. 
Indications: it is indicated for the treatment of allergic 
conjunctivitis of diverse etiology (29). 
 A single dose of ketotifen was superior to a 2-week four-
times-daily regimen of cromolyn in alleviating symptoms of 
allergic conjunctivitis (49). 
Dosage: It is available as 0.025 % topical solution in 5 ml 
and 7ml packs. Recommended dose is to instill one drop in 
each affected eye every 8-12 hours. This solution is for 
topical ophthalmic use only. It is not recommended for  
injection or oral use. It is contraindicated in patients who are 
hypersensitive to any component of the product. 
Adverse reactions: generally topical ketotifen solution is 
safe for ophthalmic use. However in less than 5 % of 
patients the following ocular adverse affects may appear; 
burning or stinging sensation, allergic reaction, 
conjunctivitis, discharge, dry eyes, keratitis, lacrimation 
disorders, photophobia and rash may occur. General 
adverse effects may include flue syndrome and pharyngitis. 
In pregnant, lactating mothers and children below three 
years of age its use is not generally recommended.  
Olopatadine hydrochloride:  
Olopatadine is a new agent that exerts both mast cell 
stabilization effect and antihistaminic effect. It is highly 
potent and relatively selective H1  receptor antagonist that 
inhabits in vivo and in vitro type-1 immediate 
hypersensitivity reaction. It has no effect in alpha 
adrenergic dopamine muscarinic type 1 and 2 and 
serotonin receptors. 
Olopatadine has been reported to have low systemic 
exposure following topical administration. Clinical trials had 
shown that it has more than 90 percent inhibition of 
basophill and mast cell degranulation and histamine 
induced conjunctival vascular permeability.  
Olopatadine is indicated for the treatment of allergic 
conjunctivitis of diverse etiology. 
Dosage and administration: Olopatadine is available as 
0.1% topical ophthalmic solution in 5ml vial. The 
recommended dose is 1-2 drops in each affected eye 3-4 
times per day (every 6-8 hours). 
Olopatadine ophthalmic solution is available for topical use 
only. It is contraindicated in those patients who are 
hypersensitive to any component of this product. 
Patients are instructed not to wear contact lenses during 
treatment with olopatadine. In pregnant, lactating mothers 
and children below 3 years of age, its use is not generally 
recommended.  
Adverse reactions: Ophthalmic adverse effects reported 
are burning or stinging sensation, dry eye, foreign body 
sensation, hyperemia, lid oedema and pruritus.  
Systemic effects include headache, cold syndrome, 
pharyngitis, sinusitis and taste perversion (29).  
 
 
Prostaglandin Inhibitors: 
Coincident with his studies on the effect of 
prostaglandins on the outer eye, Abelson and his co-
workers suggested the use of oral aspirin in the treatment 
of VKC (8). The efficacy of aspirin was also confirmed in 
other studies (50). 
Aspirin: has been proved effective in controlling symptoms 
in patients of VKC unresponsive to sodium cromoglycate 
and corticosteroid.   
Dosage: 0.5-1.5gm daily for 4-6 week period (29).  
Topical NSAIDs: Are effective in ocular allergy.  
Topical suprofen (1%) is effective in managing the signs 
and symptoms of VKC. 
Dose: 1-2 drops 3 times a day for 4-6 weeks (29).  
Ketorolac (Acular) is a nonsteroidal anti-inflammatory drug 
that blocks the release of prostaglandins by blocking 
enzyme cyclooxygenase and breaks the itch-rub cycle. 
 Dosage: 1 drop 4 times a day (5). 
Corticosteroids: 
Corticosteroids inhibit mediator biosynthesis and disrupt 
intercellular communications by preventing the release of 
lymphokines. They are the most effective and the best-
proved treatment for VKC especially when the keratitis is 
active. If possible, a weak steroid such as flouromethalone 
should be used rather than dexamethasone or prednislone. 
This is because even when used for prolong periods, 
flouromethalone does not usually results in elevation of IOP 
in susceptible individuals (4) and proved to be safe in 
children (5,6,16,18,29).  
Acetylcysteine: 
One of the common clinical findings is the tenacious 
mucus that develops. This may take any of three forms: 
mucus adhering to the cobblestones, thick and ropy strands 
of mucus or filamentary keratitis. Acetylcysteine is known to 
break the disulfide bonds, thereby dissolving the mucus and 
it is effective for all three types of excessive mucus (4, 5). 
Immunosuppressive Agents: 
Immunosuppressive medication may be beneficial. 
Cyclosporin A binds to cyclophilin, an intracellular protein, 
which in turn prevents the formation of interleukin-2 and the 
subsequent recruitment of activated T cells.  It has been 
used successfully to treat VKC. 
Topical cyclosporine 2%has been clinically tried with a 
dosage of one drop 4 times a day. There was complete 
improvement in symptoms in more than 80% of cases with 
VKC. Unlike systemic cyclosporine, topical preparations are 
relatively free of adverse effects and hold a promising future 
in the treatment of various ocular allergic disorders (4, 5,29). 
     Cryotherapy: 
Several reports have advocated the use of cryotherapy in 
the treatment of VKC. Sankar kumar and colleagues treated 
the conjunctiva of 30 eyes in 15 patients with a glaucoma 
probe at -60°C and -80°C, repeating the freeze-thaw cycle 
two to three times. They concluded that cryotherapy was 
helpful in the management of limbal nodules of VKC. 
However, they also gave the patients 0.5 to 1.5 g of aspirin. 
Therefore, it is difficult to distinguish the effect of the 
cryotherapy from that of the aspirin (5).  
Surgery: 
Surgical removal of a plaque in the base of a vernal ulcer 
preventing re-epithelialization may promote healing. 
Tarsectomy with or without mucous membrane graft has 
been suggested to physically remove the cobblestone 
papillae. However, these reports appear to lack long-term 
follow-up. Mucous membrane grafting has been reported to 
improve symptoms in vernal conjunctivitis, although there 
has been controversy in the literature regarding this 
procedure (5, 51). 
ß-Irradiation: 
Several authors have reported success with ß-irradiation 
in the treatment of VKC. However, one of the authors of this 
article (ELS) has seen permanent scarring from this 
treatment, and the lack of publications in the modern 
literature suggests that this mode of therapy no longer has 
a place in the treatment of VKC. (5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 OBJECTIVES 
1.3.1 General objective: 
This study aims to evaluate from a clinical point of view the 
role of sodium cromoglycate in treatment of VKC. 
1.3.2 Specific objectives: 
• To specify the effect of sodium cromoglycate in 
reliving symptoms and signs of VKC.  
• To detect the efficacy of sodium cromoglycate as a 
prophylactic therapy decreasing the frequency of 
attacks of active VKC.    
 
  
 
 
 
 
 
 
 
2.1 MATERIAL AND METHODS 
2.1.1 Setting:  
In this study 97 patients of both sex with VKC were clinically 
studied during the period from Jan. to June 2004. 
2.1.2 Study design: 
This is a single masked interventional case control hospital 
based study. 
The study sample was randomly divided into two groups:  
A study group of 68 patients received sodium cromoglycate and a 
control group of 29 patients received tears naturale as placebo for 
comparison.   
2.1.3 Study Area:  
This study was conducted in Makkah Eye Complex 
Khartoum- Sudan.   
2.1.4 Study Population: 
Ninety-seven patients (59 males and 38 females) with VKC 
were included in this study. Their mean age was 11.32 years, 
ranging from 2 to 34 years. 
 
 
 
2.1.5 Inclusion and Exclusion Criteria: 
2.1.5. 1 Inclusion Criteria:  
-All patients with VKC who had not received any VKC 
targeted therapy for a period of 2 weeks before the study. 
-Patients discovered and diagnosed for the first time as VKC 
cases (not treated before).  
2.1.5.2 Exclusion Criteria: 
-All patients with VKC who were taking medications two 
weeks prior to the first day of examination (base line examination).  
-VKC patients who received sodium cromoglycate before as 
treatment alone or as a part of medical therapy.   
-Patients who developed hypersensitivity for sodium 
cromoglycate or its preservative. 
-Patients with vernal ulcer.   
2.1.6 Procedure:  
The diagnosis of VKC was based on history of symptoms 
(redness, itching, tearing, etc) and signs (conjunctival papillary 
hypertrophy, giant papillae, hyperaemia, gelatinous infiltration of 
the limbus, Trantas' dots and superficial punctate keratitis). 
2.1.6.1 The Questionnaire: 
A questionnaire was pre-coded and contains information 
concerning:-  
-Personal data. 
-History of systemic and ocular diseases.  
-Family history of VKC or other atopy.  
-Medication used before. 
2.1.6.2 Examination: 
A full ocular examination was performed by the author and 
the symptoms and signs were graded and recorded.   
1st day examination = base line examination  
1st visit = after two weeks  
2nd visit = after four weeks  
2.1.6.3 Treatment: 
Steroid: (in a form of flouromethalone 4times per day) was given 
to all patients in the 1st day and stopped in the 1st visit.  
Sodium cromoglycate: (4 times per day 2% for children below 16 
years of age and 4% above that) was given to the study group in 
the 1st day and continued till the 2nd visit. 
Tears naturale: (4times per day) was given to the control group as 
placebo in the 1st day and continued till the 2nd visit.   
2.1.6.4 Grading of Symptoms and Signs: 
-Grading of symptoms and signs was done at the visit time.  
-In young children grading of symptoms was depend on their 
parent's opinion. 
2.1.6.4.1 Grading of Symptoms: 
     The major symptoms of VKC including itching, watering, 
redness, photophobia, foreign body sensation, and discharge 
were recorded separately and graded. We applied grade 0 for no 
symptoms, grade 1 for mild symptoms, grade 2 for moderate 
symptoms, and grade 3 for severe symptoms.  
2.1.6.4.2 Grading Of Signs 
     The following signs were assessed: hyperaemia, gelatinous 
infiltration of the limbus, punctate keratitis and Trantas' dots. 
Hyperaemia and gelatinous infiltration of the limbus were graded 
as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Punctate 
keratitis was graded as follows: 0 = none, 1 = 1 quadrant affected, 
2 = 2 quadrants affected, 3 = 3 or more quadrants affected. 
Trantas' dots were graded as follows: 0 = none, 1 = 1 dot, 2 = 2 or 
3 dots, 3 = more than 3 dots. 
2.1.7 Study tools: 
Materials in this study include:-  
- Snellen chart 
 -Light pin tourch                               
- Direct ophthalmoscope   
 -Slit lamp                                      
-  Eye drops (local anaesthesia and mydriatic)  
-Fluorescein strips 
-Trial set  
-Retinoscope 
2.1.8 Data Analysis 
The data was analyzed by SPSS-12 software. 
2.1.9 Ethical consideration  
A verbal consent was taken from the patients or the parents in 
cases of small children included in this study.  
2.1.10 Limitation of the study   
-Patients enrolled but not complying with the treatment schedule 
or follow up were excluded. 
  
  
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
3 RESULTS  
3.1 Socio-demographic data: 
3.1.1 Age distribution among the study population:  
Most of the study population was below the age of 20 years 
(92%) with the peak age between 10-14 years (table3.1). 
3.1.2 Sex distribution among the study population: 
Fifty nine patients (61%) were males and 38 patients (39%) 
were female (figure 3.1) and (table3.1). 
3.1.3 Distribution of the study population according to 
residence:  
Most of the patients were living in Khartoum state but 
originally they were from Northern Sudan (45%), Western Sudan 
(38%), Central Sudan (13%), Southern Sudan (2%) and Eastern 
Sudan (2%) (figure 3.2).   
3.2 Past ocular history: 
Seventy eight patients (80.4%) had a past history of VKC 
and 19 patients had no past history of the disease (figure 3.3).   
Six patients only had a past ocular history of keratoconus (three 
patients), squint (two patients) and retinitis pigmentosa (one 
patient).   
3.3 Family history of VKC or other atopy among the study 
population: 
Sixty two patients (64%) had no family history of VKC and 
22 patients had a family history of other atopy e.g. asthma, 
eczema (table3.2).   
3.4Presenting complaints (symptoms) of the study 
population:  
3.4.1Base line presenting symptoms:  
Almost all patients (except one) were complaining of itching 
at presentation, 82%of them had its severe form, 64% of the 
patients complained of severe redness or discoloration of their 
eyes. About one third of the patients (33%) presented with severe 
photophobia, 42.3% presented with severe lacrimation, 34% 
presented with severe mucoid discharge and 41.5% of the 
patients presented with severe foreign body sensation (table3.3).                         
3.4.2 1st visit (after two weeks) 
By the end of the first two weeks there was a remarkable 
improvement in both study and control groups. This improvement 
was statistically significant since the P value was 0.00. 
  This improvement manifested among the study group (using 
sodium cromoglycate and steroid) as follows; lacrimation and 
discharge disappeared completely or became minimal in 95% of 
patients, (tables 3.6, 3.7), photophobia disappeared or reduced 
significantly in intensity in 89.7% of patients (table3.5), 89% of 
patients had no more or just mild itching (table3.4), 82.3% of 
patients declared that they have no more or just mild  eye redness 
(table3.9), foreign body sensation became absent or minimal in 
58.7% of the patients (table3.8). 
Among the control group (using placebo and steroid) the 
presenting symptoms improved as follows: photophobia 
disappeared or reduced significantly in intensity in 93% of patients 
(table3.5), discharge and lacrimation disappeared completely or 
became minimal in 89.7% and 82.7% of patients successively 
(table3.7) and (table3.6), 79.3% patients had no more or just mild 
itching and redness (table3.4, 3.9), foreign body sensation 
became absent or minimal in 75.8% of the patients (table3.9). 
3.4.3 2nd visit (after four weeks) 
In the second follow up visit the improvement that achieved in the 
first visit was maintained in the study group (using sodium 
cromoglycate only). Itching, lacrimation and discharge remained in 
the mild form or disappear completely in a significant percent of 
patients (tables 3.4, 3.6, 3.7).  
Further significant improvement occurred regarding   photophobia 
foreign body sensation and redness (tables 3.5, 3.8, 3.9). P value 
< 0.05.  
The picture was totally different in the control group. Regarding 
photophobia, discharge and foreign body sensation there was no 
significant change from first follow up visit (tables 3.5, 3.7, 3.8). 
There was significant diminution in the number of patients who 
had mild or no itching (62%) (table3.4). Lacrimation became 
absent or mild in only 79% of patients (table3.6). Redness 
disappeared or became mild in only 69% of patients (table3.9).    
3.5 Presenting signs among the study population: 
Fourteen patients were found to have ptosis (14.4%) partly 
due to lid oedema and partly mechanical due to giant papillae.  
Some patients had signs of palpepral VKC (papillary hypertrophy 
68% and giant papillae 16.5%), while others had signs of the 
limbal VKC, in the form of limbitis 65.9% and Trantas’ dots 35%. 
Both signs may coexist in some cases. Small number of patients 
had corneal involvement; corneal plaque (14 patients), corneal 
opacity (7 patients) and SPK (6 patients) table (3.10).     
 
 
 
3.5.1 Grading of signs among the study population   
3.5.1.1 Base line signs  
 As demonstrated in table (3.11) congestion (hyperaemia) was 
mild in 31 patients (32%), moderate in 32 patients (33%) and 
severe in 32 patients (33%). Severe limbitis was detected in 10 
patients (10.3%) and only one patient had severe Trantas' dots.  
3.5.1.2 1st visit (after two weeks) 
The severity of signs (hyperaemia, limbitis and Trantas' dots) was 
significantly reduced in both the study and control group (p 
value<0.05). SPK was the only exception in which there was no 
significant change (tables 3.12, 3.13, 3.14, 3.15). 
3.5.1.3 2nd visit (after four weeks) 
Hyperaemia and limbitis showed further significant improvement 
among the study group. Regarding Trantas’ dots there was no 
change from the results that obtained in the first follow up visit.  
In the control group the signs were unchanged (tables 3.12, 3.13, 
3.14, 3.15).  
 
 
  
 
 
figure(3.1)
Sex distribution of the study population 
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Table (3.1) 
Age &sex distribution among the study population  
 
 
 
 
 
 
 
 
Total Age in year Male Female Frequency Percent 
< 5 
 
5-9 
 
10-14 
 
15-19 
 
20-24 
 
25-29 
 
> 30 
 
14 
 
12 
 
16 
 
15 
 
1 
 
0 
 
1 
7 
 
10 
 
8 
 
8 
 
2 
 
3 
 
0 
 
 
21 
 
22 
 
24 
 
23 
 
3 
 
3 
 
1 
 
 
21.65% 
 
22.68% 
 
24.75% 
 
23.71% 
 
3.09% 
 
3.09% 
 
1.03% 
 
Total 59 38 97 100% 
 
 
Table (3. 2) 
Family history of VKC or other atopy among the study population 
 
VKC Other atopy Family History Frequency Percent Frequency Percent 
Positive 
 
 
Negative 
 
 
35 
 
 
62 
 
 
36% 
 
 
64% 
 
 
22 
 
 
75 
 
 
22.7% 
 
 
77.3% 
 
 
Total 97 100% 97 100% 
 
 
 
 
 
 
 
 
 
 
 
 
           Table (3.3) 
          Presenting complaints (symptoms) of the study population 
    
Grading 
No Mild Moderate Severe 
Total Symptom 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent
Itching  
 
Photophobia 
 
Lacrimation 
 
Discharge 
 
Foreign body 
sensation 
 
Discoloration 
 
1 
 
39 
 
27 
 
25 
 
29 
 
 
9 
 
 
1.03% 
 
40.21% 
 
27.83% 
 
25.80% 
 
37.66% 
 
 
9.30% 
 
3 
 
10 
 
14 
 
20 
 
6 
 
 
11 
3.09% 
 
10.31% 
 
14.44% 
 
20.60% 
 
7.79% 
 
 
11.30% 
13 
 
16 
 
15 
 
19 
 
10 
 
 
13 
13.40% 
 
16.49% 
 
15.46% 
 
19.58% 
 
12.99% 
 
 
13.40% 
80 
 
32 
 
41 
 
33 
 
32 
 
 
64 
82.47% 
 
32.99% 
 
42.27% 
 
34.02% 
 
41.56% 
 
 
66.00% 
96 
 
58 
 
70 
 
72 
 
48 
 
 
88 
 
98.97% 
 
59.79% 
 
72.17% 
 
74.20% 
 
62.34% 
 
 
90.70% 
 
Table (3.4) 
Grading of itching among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group Itching 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
0 
 
3 
 
10 
 
55 
 
0% 
 
4.41% 
 
14.71% 
 
80.88% 
 
1 
 
0 
 
3 
 
25 
 
3.45% 
 
0% 
 
10.34% 
 
86.21% 
 
32 
 
29 
 
5 
 
2 
 
47.06% 
 
42.65% 
 
7.35% 
 
2.94% 
 
9 
 
14 
 
5 
 
1 
 
31.03% 
 
48.28% 
 
17.24% 
 
3.45% 
 
38 
 
21 
 
2 
 
7 
 
55.88% 
 
30.88% 
 
2.95% 
 
10.29% 
 
2 
 
16 
 
6 
 
5 
 
6.90% 
 
55.17% 
 
20.69% 
 
17.24% 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
Table (3. 5) 
Grading of Photophobia among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
Photophobia 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
38 
 
21 
 
2 
 
7 
 
 
55.88% 
 
30.88% 
 
2.94% 
 
10.30% 
 
 
13 
 
2 
 
6 
 
8 
 
 
44.83% 
 
6.90% 
 
20.69% 
 
27.58% 
 
 
53 
 
8 
 
6 
 
1 
 
 
77.94% 
 
11.76% 
 
8.82% 
 
1.48% 
 
 
19 
 
8 
 
1 
 
1 
 
 
65.52% 
 
27.58% 
 
3.45% 
 
3.45% 
 
 
60 
 
4 
 
3 
 
1 
 
 
88.23% 
 
5.88% 
 
4.41% 
 
1.48% 
 
 
20 
 
7 
 
2 
 
0 
 
 
68.96% 
 
24.14% 
 
6.90% 
 
0% 
 
 
Total     68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
Table (3.6) 
 
Grading of Lacrimation among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
Lacrimation 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
20 
 
9 
 
12 
 
27 
 
 
29.41% 
 
13.23% 
 
17.65% 
 
39.71% 
 
 
7 
 
5 
 
3 
 
14 
 
 
24.14% 
 
17.24% 
 
10.34% 
 
48.28% 
 
 
47 
 
17 
 
2 
 
2 
 
 
69.12% 
 
25.00% 
 
2.94% 
 
2.94% 
 
 
19 
 
5 
 
5 
 
0 
 
 
65.52% 
 
17.24% 
 
17.24% 
 
0% 
 
 
51 
 
12 
 
2 
 
3 
 
 
75.00% 
 
17.65% 
 
2.94% 
 
4.41% 
 
 
12 
 
11 
 
6 
 
0 
 
 
41.38% 
 
37.93% 
 
20.69% 
 
0% 
 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
 
 
 
Table (3.7) 
Grading of Discharge among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
Discharge 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
15 
 
14 
 
14 
 
25 
 
 
22.05% 
 
20.59% 
 
20.59% 
 
36.77% 
 
 
10 
 
6 
 
5 
 
8 
 
 
34.48% 
 
20.69% 
 
17.24% 
 
27.59% 
 
 
48 
 
17 
 
2 
 
1 
 
 
70.58% 
 
25.00% 
 
2.94% 
 
1.48% 
 
 
20 
 
6 
 
2 
 
1 
 
 
68.96% 
 
20.69% 
 
6.90% 
 
3.45% 
 
 
56 
 
6 
 
3 
 
3 
 
 
82.35% 
 
8.82% 
 
4.41% 
 
4.41% 
 
 
16 
 
10 
 
1 
 
2 
 
 
55.17% 
 
34.48% 
 
3.45% 
 
6.90% 
 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
 
 
 
 
 
 
 
Table (3. 8) 
Grading of Foreign body sensation among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
Foreign 
body 
sensation Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
Non 
     
18 
 
5 
 
6 
 
20 
 
19 
 
 
26.47% 
 
7.35% 
 
8.83% 
 
29.41% 
 
27.94% 
 
 
11 
 
1 
 
4 
 
12 
 
1 
 
 
37.93%
 
3.45% 
 
13.79%
 
41.38%
 
3.45% 
 
 
30 
 
10 
 
7 
 
2 
 
19 
 
 
44.12%
 
14.70%
 
10.30%
 
2.94% 
 
27.94%
 
 
19 
 
3 
 
5 
 
1 
 
1 
 
 
65.52%
 
10.34%
 
17.24%
 
3.45% 
 
3.45% 
 
 
36 
 
11 
 
1 
 
1 
 
19 
 
 
52.94% 
 
16.17% 
 
1.48% 
 
1.48% 
 
27.94% 
 
 
18 
 
4 
 
3 
 
3 
 
1 
 
 
62.07%
 
13.80%
 
10.34%
 
10.34%
 
3.45% 
 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
 
 
Table (3. 9) 
Grading of redness or Discoloration among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
Discoloration 
or redness 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
4 
 
9 
 
7 
 
48 
 
5.88% 
 
13.24% 
 
10.30% 
 
70.58% 
 
 
5 
 
2 
 
6 
 
16 
 
 
17.24% 
 
6.90% 
 
20.69% 
 
55.17% 
 
 
29 
 
27 
 
8 
 
4 
 
 
42.65% 
 
39.71% 
 
11.76% 
 
5.88% 
 
 
12 
 
11 
 
4 
 
2 
 
 
41.38% 
 
37.92% 
 
13.80% 
 
6.90% 
 
 
42 
 
18 
 
3 
 
5 
 
 
61.76% 
 
26.48% 
 
4.41% 
 
7.35% 
 
 
7 
 
13 
 
4 
 
5 
 
 
24.13% 
 
44.83% 
 
13.80% 
 
17.24% 
 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
Table (3.10)  
Presenting signs among study population 
 
Sign Frequency Percent 
Ptosis 
 
Lid oedema 
 
Blepharitis 
 
Hyperaemia 
 
Limbitis 
 
Trantas' spot  
 
Superficial punctate 
keratitis 
 
Papillary Hypertrophy 
 
 Giant Papillae 
 
Corneal Scar 
 
Pannus 
 
Corneal plaque 
 
Corneal opacity 
 
Keratoconnus 
 
14 
 
21 
 
2 
 
95 
 
           64 
 
34 
 
6 
 
 
66 
 
 
16 
 
5 
 
11 
 
14 
 
7 
 
3 
 
14.43% 
 
21.64% 
 
2.06% 
 
97.93% 
 
        65.97% 
 
35.05% 
 
6.18% 
 
 
68.04% 
 
 
16.49% 
 
5.15% 
 
11.34% 
 
14.43% 
 
7.21% 
 
3.09% 
 
Table (3. 11) 
Baseline grading of signs among the study population  
 
  
Grading 
No Mild Moderate Severe 
Total Sign 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
Hyperemia 
 
Limbitis 
 
Trantas' 
spot 
 
Superficial 
punctate 
keratitis 
 
2 
 
33 
 
63 
 
91 
2.10% 
 
34% 
 
64.95%
 
93.82%
31 
 
24 
 
19 
 
3 
31.90%
 
24.75%
 
19.59%
 
3.09% 
32 
 
30 
 
14 
 
3 
33% 
 
30.94% 
 
14.43% 
 
3.09% 
32 
 
10 
 
1 
 
0 
33% 
 
10.31%
 
1.03% 
 
0% 
95 
 
64 
 
34 
 
6 
 
97.9% 
 
66.00%
 
35.05%
 
6.18% 
 
Table (3.12) 
Grading of Hyperaemia among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
Hyperemia 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
1 
 
24 
 
21 
 
22 
 
1.47% 
 
35.29% 
 
30.88% 
 
32.36% 
 
 
1 
 
7 
 
11 
 
10 
 
 
3.45% 
 
24.14% 
 
37.93% 
 
34.48% 
 
 
25 
 
36 
 
4 
 
3 
 
 
36.76% 
 
52.95% 
 
5.88% 
 
4.41% 
 
 
10 
 
16 
 
3 
 
0 
 
 
34.48% 
 
55.17% 
 
10.35% 
 
0% 
 
 
48 
 
16 
 
1 
 
3 
 
 
70.59% 
 
23.53% 
 
1.47% 
 
4.41% 
 
 
6 
 
16 
 
7 
 
0 
 
 
20.69% 
 
55.17% 
 
24.14% 
 
0% 
 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
 
 
 
Table (3.13) 
Grading of Limbitis among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
Limbitis 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
23 
 
16 
 
22 
 
7 
 
 
33.83% 
 
23.53% 
 
32.35% 
 
10.29% 
 
 
10 
 
8 
 
8 
 
3 
 
 
34.48% 
 
27.59% 
 
27.59% 
 
10.34% 
 
 
40 
 
23 
 
3 
 
2 
 
 
58.82% 
 
33.83% 
 
4.41% 
 
2.94% 
 
 
17 
 
8 
 
4 
 
0 
 
 
58.62% 
 
27.59% 
 
13.79% 
 
0% 
 
 
57 
 
8 
 
3 
 
0 
 
 
83.82% 
 
11.77% 
 
4.41% 
 
0% 
 
 
13 
 
12 
 
4 
 
0 
 
 
44.83% 
 
41.38% 
 
13.79% 
 
0% 
 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
 
 
Table (3.14) 
Grading of Trantas' spot among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
Trantas' 
spot 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
45 
 
12 
 
11 
 
0 
 
 
66.18% 
 
17.65% 
 
16.17% 
 
0% 
 
 
18 
 
7 
 
3 
 
1 
 
 
62.07% 
 
24.14% 
 
10.34% 
 
3.45% 
 
 
56 
 
10 
 
2 
 
0 
 
 
82.35% 
 
14.71% 
 
2.94% 
 
0% 
 
 
21 
 
7 
 
1 
 
0 
 
 
72.41% 
 
24.14% 
 
3.45% 
 
0% 
 
 
62 
 
4 
 
2 
 
0 
 
 
91.18% 
 
5.88% 
 
2.94% 
 
0% 
 
 
21 
 
8 
 
0 
 
0 
 
 
72.41% 
 
27.59% 
 
0% 
 
0% 
 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
 
 
 
 
 
 
 
 
Table (3.15) 
Grading of Superficial punctate keratitis among study population 
 
 
1st day 1st visit 2nd visit 
Study group Control group Study group Control group Study group Control group 
SPK 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
No 
 
Mild 
 
Moderate 
 
Severe 
 
66 
 
0 
 
2 
 
0 
 
 
97.06% 
 
0% 
 
2.94% 
 
0% 
 
 
25 
 
3 
 
1 
 
0 
 
 
86.21% 
 
10.34% 
 
3.45% 
 
0% 
 
 
66 
 
2 
 
0 
 
0 
 
 
97.06% 
 
2.94% 
 
0% 
 
0% 
 
 
26 
 
3 
 
0 
 
0 
 
 
89.66% 
 
10.34% 
 
0% 
 
0% 
 
 
67 
 
1 
 
0 
 
0 
 
 
98.53% 
 
1.47% 
 
0% 
 
0% 
 
 
26 
 
3 
 
0 
 
0 
 
 
89.66% 
 
10.34% 
 
0% 
 
0% 
 
 
Total 68 100% 29 100% 68 100% 29 100% 68 100% 29 100% 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.1 Discussion 
Most of the patients in our study were below the age of 20 
years. From this large group about 67 children were affected, this 
is confirmed by what was mentioned in the literature that VKC is 
usually a disease of children (52) which begins in prepubertal years 
and lasts for 5 – 10 years (53).  
The majority of patients in our study were males (60.8%). 
The disease occurs more often in boys than in girls. This was also 
mentioned in literature (18.19.21) and goes with our findings. While 
Duane showed that only one series pointed out to a female 
preponderance (5).  
All patients included in this study were living in Khartoum 
state but originally most of them (44.3%) were from Northern 
Sudan, a state known by its dry & hot weather. The disease is 
more common in tropics and Sudan is one of the tropical 
countries. This disease is almost always more sever during the 
spring, summer & fall then in winter (53).  
In Sudan the severity is usually due to dusty and sandy 
winds, and grass pollen sensitivity in transitional period between 
winter and autumn.  
The majority of patients had past history of VKC and this 
indicates the recurrence of the disease with a strong history of 
allergies.  
It is known as seasonal or warm weather conjunctivitis, the 
identification of specific allergens is still a mystery (53). 
It is a hypersensitivity reaction to exogenous allergens and 
is mediated by IgE as indicated by the accompanying easinophilia 
(18).    
Family history of atopy in patients with VKC was mentioned 
by Kanski, Duane and Yanof(4,5,6). This confirms our finding. One 
third of the patients in our study had a family history of VKC and 
one fourth had a family history of atopy. 
The main presenting symptom among our study population 
was itching; it has been described as the main symptom of VKC 
(4,18,20).  
It is mentioned in the literature that the chief complaint of 
VKC are photophobia, lacrimation and mucoid discharge being 
the second after itching, in our study redness or discoloration was 
the second presenting complaint and this may be explained by 
two factors: a racial factor, most of the Sudanese people are black 
skin indicating more pigmentation and a climatic factor where 
most of the year weather in Sudan is hot and dry with dusty winds 
which irritates the eye making it red. The claim that discoloration 
is changing according to the severity of the disease may be due to 
the overlapping by redness.  
In the first follow up, all patients (study and control groups) 
showed significant improvement of their previous complaints. This 
improvement is mostly due to the anti-inflammatory effects of 
steroids. Sodium cromoglycate has no direct antihistaminic effect 
and must be used prophylacticaly   for several weeks to be 
effective (18).  
In the second follow up when steroids have been stopped 
and treatment was continued only with either sodium 
cromoglycate or placebo, the study group showed continuous 
stationary improvement as regarding itching, lacrimation and 
discharge, the chief symptoms of VKC. Further significant 
improvement occurs in photophobia, foreign body sensation and 
redness. 
 This result can be attributed to mast cell stabilization effect 
of sodium cromoglycate as a prophylactic drug.   
 Among the control group itching, redness and lacrimation 
were getting worse. While photophobia, F.B. sensation and 
discharge were remain at the same level. This may be explained 
by the soothing and washing effect of tears naturale.  
 This confirms what other studies concluded, that sodium 
cromoglycate is more effective in reliving symptoms of VKC than 
placebo (40, 41, 45). 
 The presenting signs: 
The first examination of the study population revealed that 
hyperaemia was the most common presenting sign followed by 
papillary hypertrophy, limbitis and Trantas' dots. 
Hyperaemia is a characteristic finding in both palpebral & 
bulbar or limbal VKC and this goes with our findings that 
hyperemia was detected in about 98% of our patients. 
Papillary hypertrophy and limbitis occurred nearly by the 
same percentage. This may be explained by that in the palpebral 
VKC, papillary hypotrophy is a characteristic finding while in 
bulbar or limbal VKC limbitis is the characteristic sign and both are 
present in the combined type of VKC. 
Trantas' dots which is a pathognomonic sign of the bulbar 
type of VKC was detected in about one third of the study 
population. This finding is confirmed by what was  mentioned in 
the literature that limbal VKC is more common in black patients (4)  
. 
Corneal signs are much less compared with palpebral & 
bulbar signs. Among the corneal signs, corneal plaque was the 
commonest. It is known that the plaque is usually caused by 
epithelial macro erosions, in which the base becomes coated with 
layers of altered exudation which can not be wetted by tears and 
resist re-epithelization .This may explain why its percentage is 
high among the corneal findings. 
SPK was detected in about 6% of all the study population 
and accounted for about 15% only among the corneal signs. 
Although it was known to be the commonest corneal sign in VKC, 
in our study it was the 3rd sign after plaque and corneal opacity. 
This may be explained by the fact that both plaque and corneal 
opacities occurred as a complication of epithelial macro erosion. 
The first follow up: 
As regarding the signs of VKC among our study population 
there was a significant improvement in the presenting signs 
especially hyperaemia, limbitis and Trantas' spot. This 
improvement was with no doubt due to the effect of steroids. 
As regarding corneal signs especially SPK there was no 
considerable improvement, this may be explained by the fact that 
none of the corneal lesions respond well to standard treatment (53) 
or this may be because of the small number of patients with 
corneal manifestations in our study. Evaluation of this finding 
needs more patients with corneal manifestations. These findings 
were the same for both study and control groups. 
The second follow up: 
Among the study group there was marked improvement of 
VKC signs namely hyperaemia, limbitis and Trantas' spot 
especially in the moderate and severe cases. This signifies the 
role of sodium cromoglycate .Topical Sodium cromoglycate is a 
useful prophylactic agent in moderate to severe cases of VKC (53). 
Among the control group the signs were slightly improved "not 
significant” from the first day of examination up to the second visit, 
this may be due to the prolong effect of topical steroids. 
 
 
 
 
 
4.2 Conclusions 
1. Sodium cromoglycate is a useful prophylactic agent in the 
treatment of VKC. 
2. Steroids were effective in eliminating severe symptoms and 
signs of VKC. 
 
        
     
3.3 Recommendations 
 
1. More scientific researches and studies are required to 
identify the specific allergen or allergens which is/are still a 
mystery cause of VKC. 
2. Discourage the use of the steroids in the treatment of VKC 
unless it is necessary and for short time. 
3. Encourage the use of sodium cromoglycate and other mast 
cell stabilizers as it is proved to be effective as a 
prophylactic agent in the treatment of VKC. 
4. Complementary study is needed to evaluate the effect of 
sodium cromoglycate in decreasing the severity of 
symptoms and signs of VKC prior to the time of 
exacerbation. 
5. Advice patients of VKC to: 
• Use sunglasses and avoid heat and dust 
• Sleeping and if possible working in a cool air-conditioned 
rooms 
• Move to cool moist climate if possible. 
These advices can keep the patients reasonably comfortable. 
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EFFECT OF SODIUM CROMOGLYCATE IN SUDANESE PATIENTS 
WITH VERNAL KERATOCONJUNCTIVITIS 
 
QUESTIONNAIRE 
 
 
PERSONAL DATA 
 
CASE  NO: ------------------- 
 
NAME: -------------------------------AGE-------------GENDER------------- RESIDENCE ------- 
 
FAMILY HISTORY: ------------------- PAST OCCULAR HISTORY--------------------- 
 
OCCULAR MEDICATION------------------- 
 
OTHER SENSITIVITY: -------------------------- 
 
SYSTEMIC DISESAE   
ASTHMA [____] 
   ECZEMA [____] 
   OTHERS  [____] 
CHIEF COMPLAINTS 
SYMPTOMS 
ITCHING IST DAY 2ND WEEK 4TH WEEK 
o NONE=0 
o MILD=1 
o MODERATE=2 
o SEVERE=3 
   
PHOTOPHOBIA    
o NONE=0 
o MILD=1 
o MODERATE=2 
o SEVERE=3 
   
LACRIMATION    
o NONE=0 
o MILD=1 
o MODERATE=2 
o SEVERE=3 
   
DISCHARGE    
o NONE=0 
o MILD=1 
o MODERATE=2 
o SEVERE=3 
   
F.B SENSATION    
o NONE=0 
o MILD=1 
o MODERATE=2 
o SEVERE=3 
   
REDNESS OR BROWN 
DISCOLORATION 
   
o NONE=0 
o MILD=1 
o MODERATE=2 
o SEVERE=3 
   
 
 
EXAMINATION 
VA------------R-----------L--------------   REFRACTION----------------------------
--- 
 
VA/CORRECTED----------R---------L----------         OCCULAR MOVEMENT-------------------------
--- 
 IST DAY 2ND WEEK 4TH WEEK 
EYE LID    
 PTOSIS 
 OEDEMA 
ENTROPION 
ECZEMA 
   
LID MARGIN    
MADAROSIS 
TRICHIASIS  
BLEPHARITIS                        
   
PALPEBERALCONJUNCTIVA    
 HYPERAEMIA                      
PAPILARY HYPERTROPHY 
GIANT PAPILLAE (COBBLE 
STONE)     
SCAR 
   
BULBAR CONJUNCTIVA     
HYPERAEMIA  
CHEMOSIS                                    
DISCOLORATION 
   
LIMBUS    
GELATENOUS MATERIAL 
 TRANTAS' SPOT  
   
CORNEA    
 S.P.K 
PANNUS 
MACRO EROSION 
CORNEAL ULCER 
CORNEAL PLAQUE 
SUP.VASCULARIZATION  
DEEP VASCULARIZATION 
CORNEAL OPACITY 
KERATOCONUS 
   
EPISCLERA  
 
  
SCLERA  
 
  
ANTERIOR CHAMBER  
 
  
IRIS  
 
  
LENS  
 
  
RETINA  
 
  
         
TREATMENT   SODIUM CROMOGLYCATE [____]    [____] 
   STEROIDS            [____]    [____] 
   TEARS NATURALE              [____]    [____] 
 
 
